Correction to: Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC
verfasst von:
Bradley R. Groveman, Christina D. Orrù, Andrew G. Hughson, Lynne D. Raymond, Gianluigi Zanusso, Bernardino Ghetti, Katrina J. Campbell, Jiri Safar, Douglas Galasko, Byron Caughey
In the original publication of this article [1] the plasmid name is incorrect in the first sentence of the “K23Q rαSyn expression vector preparation” section of Materials and methods.
The correct and incorrect information is shown below in bold.
Correct: DNA sequences coding for human α-synuclein sequence (Accession No. NM_000345.3) amino acid residues 1–140 (wildtype) were amplified and ligated into the pET28 vector with an N-terminal His-tag (EMD Biosciences) and sequences were confirmed.
Incorrect: DNA sequences coding for human α-synuclein sequence (Accession No. NM_000345.3) amino acid residues 1–140 (wildtype) were amplified and ligated into the pET24 vector with an N-terminal His-tag (EMD Biosciences) and sequences were confirmed.
Anzeige
Furthermore, the original publication contained an incorrrect version of figure 4. The error in this figure is: exponents in the SD50/mg column of panel A are negative, when they should be positive. This correction article contains the correct version of Fig. 4.
Fig. 4
End-point dilutions of synucleinopathy BH (a; sample # 081017) or CSF (b; sample # 10/005) samples by αSyn RT-QuIC. Each sample trace represents the average ThT signal of quadruplicate wells. Tables to the right of each graph indicate the concentration of SD50 units calculated by Spearman–Kärber analysis for these, and additional, cases. End-point dilution experiments used for the additional calculated values shown in the upper and lower panels are provided in Additional files 4 and 5, respectively
×
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Correction to: Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC
verfasst von
Bradley R. Groveman Christina D. Orrù Andrew G. Hughson Lynne D. Raymond Gianluigi Zanusso Bernardino Ghetti Katrina J. Campbell Jiri Safar Douglas Galasko Byron Caughey
Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.
Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.
Update Neurologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
